Analyst Reco. Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-02-17 EST			5-day change	1st Jan Change
4.500 ^USD	-0.66%		-3.23%	+24.65%

02-03	Obesity stocks slump on Novo's underwhelming 2026 sales forecast	RE
01-28	Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target	MT

Analyst Reco.

01-28	Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target	MT
25-08-13	UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating	MT
25-08-13	B. Riley Adjusts Price Target on Altimmune to $18 From $20, Maintains Buy Rating	MT
25-02-28	William Blair Initiates Altimmune at Market Perform	MT
25-01-08	Stifel Initiates Altimmune at Buy With $18 Price Target	MT
24-11-12	UBS Initiates Altimmune at Buy With $26 Price Target	MT
24-04-29	Altimmune Shares Decline After Guggenheim Downgrade	MT
24-04-29	Guggenheim Downgrades Altimmune to Neutral From Buy	MT
24-01-17	B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	MT
23-11-09	B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	MT
23-08-11	B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	MT
23-08-10	B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	MT
23-03-22	Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	MT
23-01-20	HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	MT
23-01-18	Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	MT
22-12-01	Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	MT
22-11-11	JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	MT
22-09-28	Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight	CI
22-09-16	Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	MT
22-08-31	Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	MT
22-08-17	HC Wainwright Adjusts Altimmune's Price Target to $50 From $25, Reiterates Buy Rating	MT
22-08-12	B. Riley Securities Raises Altimmune's Price Target to $26 from $21, Increases Likelihood of Technical, Regulatory Success; Keeps Buy Rating	MT
22-05-18	Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating	MT
22-03-16	Guggenheim Adjusts Altimmune's Price Target to $28 From $33, Reiterates Buy Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Analyst Reco.

Filters